An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

被引：0
|
作者：
Kelly, Kevin R. [1 ]
Gabrail, Nashat Y. [2 ]
Edenfield, William J. [3 ]
Lockhart, A. Craig [4 ]
Olszanski, Anthony J. [5 ]
Reddy, Guru [6 ]
机构：
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[2] Gabrail Canc Ctr, Canton, OH USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Washington Univ, Sch Med, St Louis, MO 63130 USA
[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[6] Spectrum Pharmaceut, Irvine, CA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors
    Cao, J.
    Ji, D.
    Shen, W.
    Wang, Q.
    Liu, Y.
    Lu, D.
    Sturm, I.
    Huang, F.
    Cleton, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
    Rolfo, Christian
    Isambert, Nicolas
    Italiano, Antoine
    Molife, L. Rhoda
    Schellens, Jan Hm
    Blay, Jean-Yves
    Decaens, Thomas
    Kristeleit, Rebecca
    Rosmorduc, Olivier
    Demlova, Regina
    Lee, Myung-Ah
    Ravaud, Alain
    Kopeckova, Katerina
    Learoyd, Maria
    Bannister, Wendy
    Locker, Gershon
    de Vos-Geelen, Judith
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1807 - 1818
  • [23] An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
    Tomkinson, H. K.
    Weil, A.
    Engelhardt, E.
    Schmid, K.
    Oliver, S.
    Morris, T.
    Swaisland, H.
    Taboada, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
  • [24] The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
    Durairaj, Chandrasekar
    Chakrabarti, Jayeta
    Ferrario, Cristiano
    Hirte, Holger W.
    Babu, Sunil
    Piha-Paul, Sarina A.
    Plotka, Anna
    Hoffman, Justin
    Shi, Haihong
    Wang, Diane D.
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 921 - 930
  • [25] PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT
    Rolfo, C.
    de Vos-Geelen, J.
    Isambert, N.
    Molife, L. R.
    Schellens, J. H.
    De Greve, J.
    Blay, J. -Y.
    Dirix, L.
    Grundtvig-Sorensen, P.
    Italiano, A.
    Jerusalem, G.
    Kristeleit, R.
    Leunen, K.
    Mau-Sorensen, M.
    Plummer, R.
    Learoyd, M.
    Baker, N.
    Fielding, A.
    Ravaud, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S85 - S86
  • [26] The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
    Chandrasekar Durairaj
    Jayeta Chakrabarti
    Cristiano Ferrario
    Holger W. Hirte
    Sunil Babu
    Sarina A. Piha-Paul
    Anna Plotka
    Justin Hoffman
    Haihong Shi
    Diane D. Wang
    Clinical Pharmacokinetics, 2021, 60 : 921 - 930
  • [27] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Asahina, Hajime
    Tamura, Yosuke
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Seki, Yoshitaka
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Yamada, Yasuhide
    Coates, Andrew
    Chiu, Yi-Lin
    Li, Xiaohui
    Pradhan, Rajendra
    Ansell, Peter J.
    McKeegan, Evelyn M.
    McKee, Mark D.
    Carlson, Dawn M.
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1477 - 1486
  • [28] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Hajime Asahina
    Yosuke Tamura
    Hiroshi Nokihara
    Noboru Yamamoto
    Yoshitaka Seki
    Takashi Shibata
    Yasushi Goto
    Maki Tanioka
    Yasuhide Yamada
    Andrew Coates
    Yi-Lin Chiu
    Xiaohui Li
    Rajendra Pradhan
    Peter J. Ansell
    Evelyn M. McKeegan
    Mark D. McKee
    Dawn M. Carlson
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1477 - 1486
  • [29] An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
    Pierre Maison-Blanche
    Shaker Dakhil
    Ari Baron
    Sylvie Rottey
    Fred Millard
    Gedske Daugaard
    Jean-Pascal Machiels
    William Conkright
    Sunil Sharma
    Patricia M. M. B. Soetekouw
    Jeffrey Yachnin
    Lisa Sengeløv
    Peter Van Veldhuizen
    Sanjiv S. Agarwala
    Dorothée Sémiond
    Mustapha Chadjaa
    Liji Shen
    James L. Wade
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1241 - 1252
  • [30] An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
    Maison-Blanche, Pierre
    Dakhil, Shaker
    Baron, Ari
    Rottey, Sylvie
    Millard, Fred
    Daugaard, Gedske
    Machiels, Jean-Pascal
    Conkright, William
    Sharma, Sunil
    Soetekouw, Patricia M. M. B.
    Yachnin, Jeffrey
    Sengelov, Lisa
    Van Veldhuizen, Peter
    Agarwala, Sanjiv S.
    Semiond, Dorothee
    Chadjaa, Mustapha
    Shen, Liji
    Wade, James L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1241 - 1252
12345